Today's Big Losers: NVAX, AZC, ADCT

Biotechnology company Novavax (NVAX) announced it priced a public offering of 6.8 million common ...  More »

Biotechnology company Novavax (NVAX) announced it priced a public offering of 6.8 million common shares, at 3 dollars and 30 cents each. The company said net proceeds would go toward preclinical studies and clinical trials of the company's vaccines, as well as for research and development.  « Less